Ignite Creation Date:
2024-05-06 @ 8:22 AM
Last Modification Date:
2024-10-26 @ 11:59 AM
Study NCT ID:
NCT02722941
Status:
COMPLETED
Last Update Posted:
2022-11-01
First Post:
2016-03-24
Brief Title:
Panobinostat LBH589 Multiple Myeloma - Autologous Hematopoietic Cell Transplantation HCT
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
Evaluation of Panobinostat LBH589 as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation
Status:
COMPLETED
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to learn more about ways to prevent or delay relapse of multiple myeloma MM This study will determine the best dosing schedule of LBH589 maintenance therapy as well as the safety side effects and tolerability of LBH589 maintenance therapy after autologous hematopoietic cell transplant HCT
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CLBH589DUS97T | OTHER | Novartis Pharmaceuticals | None |